Hospital Chronicles Hospital Chronicles en-US Authors who publish with this journal agree to the following terms:<br /><p>a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="" target="_new">Creative Commons Attribution License</a> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</p><p>b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</p><p>c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See <a href="" target="_new">The Effect of Open Access</a>).</p> (Editorial Office) (Manos Kollias) Thu, 21 Mar 2019 14:22:37 +0200 OJS 60 A LETTER FROM THE EDITOR <p>NO</p> Athanasios Yalouris ##submission.copyrightStatement## Thu, 21 Mar 2019 11:36:40 +0200 Human disease on stage <p>Theater, being in most cases a representation of real life, can refer to anyone of its aspects, including disease. Human disease is a specific condition associated with several effects in the behavior of both, the patient and his environment, as well as their interrelationship. Several play writers, even from the ancient years, have tried to present these effects. Furthermore, another topic for the theater can be the way Medicine is practiced, usually with a critical approach.</p> <p>Of course play writers have not in general studied Medicine and so their references to disease may not be always absolutely right, especially if they represent aspects of past time. Furthermore, if we refer to poetic or symbolic drama it may express unrealistic situations only to serve the main idea of the author.</p> Athanasios Yalouris ##submission.copyrightStatement## Thu, 21 Mar 2019 11:37:29 +0200 Procalcitonin in acute heart failure <p>Acute heart failure (AHF) isa time critical disease and it is of outmost importance to identify the underlyingprecipitating factors as soon as possible as this can improve patient outcomes. Infection is such a significant factor. Procalcitonin (PCT), as a biomarker of bacterial infection, can be used in AHF patients to establish the diagnosis of concomitant bacterial infection. PCT can guide the early initiation of antibiotic therapy and provide prognostic information regarding AHF patients. This short review summarizes the current evidence on PCT use in AHF including the preliminary results of the IMPACT-BIC-18 trial.&nbsp;</p> George Michas, Athanasios Trikas ##submission.copyrightStatement## Thu, 21 Mar 2019 11:38:10 +0200 Galectins 7 and 9 in Dermatology : Current knowledge and future perspectives <p>Galectins constitute a family of β-galactoside-binding proteins lectins that are widely distributed in nature occurring in mammals, sponges, fungi, nematodes, insects and viruses.  Galectins are involved in fundamental cellular processes in human skin and other tissues and exert biological effects of paramount importance through interactions with cytoplasmic and nuclear proteins and with components of cell surface and extracellular matrix, as well.</p><p>In this paper we summarize current knowledge on the expression of galectins 7 and 9 in normal and diseased human skin and present the future perspectives of the use of these galectins or their antagonists/inhibitors in the diagnosis, prognosis and treatment of cutaneous disorders.</p> Efstathia S Pasmatzi, Alexandra Monastirli, George Badavanis, Christina Papadionysiou, Dionysios Tsambaos ##submission.copyrightStatement## Thu, 21 Mar 2019 11:38:54 +0200 Acute post cardiac injury syndrome occurring immediately after a demanding percutaneous coronary intervention. <p>Postcardiac injury syndrome (PCIS) occurs as a complication of myocardial infarction (Dressler's syndrome), of cardiac surgery (post-pericardiotomy syndrome), or post-traumatic (either iatrogenic or non-iatrogenic) and involves a pericardial or myocardial injury. There is scarce data regarding occurrence and pathogenesis of PCIS after invasive procedures. Herein, we describe a unique case of acute PCIS with typical clinical, laboratory, echocardiographic findings that occurred one hour after a demanding multi-stenting percutaneous coronary intervention. Possible pathogenetic mechanisms and treatment options are being discussed.</p> Gerasimos Gavrielatos, George Michas, Konstantinos Grigoriou, Athanasios Trikas ##submission.copyrightStatement## Thu, 21 Mar 2019 11:39:33 +0200 Patient operated for an intraparenchymal brain tumor with serious lower limb weakness. The role of in-hospital physiotherapy <p>The aim of this case study is to present the role of hospital physiotherapy in a patient who was operated for an intraparenchymal brain tumor, from admission to intensive care unit until his discharge from hospital. Following acute surgical management, physiotherapy commenced and was devided in four phases:  1) Patient in ICU under mechanical support, 2) Patient in ICU without mechanical support, 3) Patient in step down unit, 4) Patient on the neurosurgical ward. During all phases of patient management, physiotherapy focused on daily assessment of respiratory and musculoskeletal function as well as the prevention and management of acute complications in intensive care unit and acquired physical impairments. Interventions included state of the art chest physiotherapy techniques as well as an early rehabilitation regimen from ICU to the step down unit and the ward. Significant improvements were noted before the patient was discharged, in respiratory function, muscle power and mobility. Planning and application of all physiotherapy techniques was in accordance to the most recent research evidence and clinical guidelines and contributed significantly to the patient’s overall clinical outcome.</p> Manolis Papadopoulos ##submission.copyrightStatement## Thu, 21 Mar 2019 11:40:40 +0200 Diabetes News/Recent Literature Review/ First Quarter 2018 <p><strong>Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4</strong></p> <p>The safety of metformin was examined in moderate and severe chronic kidney disease (CKD)( stages 3A/3B and 4, eGFR 59-45, 44-30, and &lt;15 mL/min/1.72 m<sup>2 </sup>, respectively). Three metformin doses were examined: 1,500mg (0.5 g in the morning [qam]+ 1g in the evening [qpm]) in CKD3A, 1,000 mg (0.5g qam + o.5 g qpm ) in CKD3B, and 500 mg (qam) in CKD 4. After 4 months on these regimens, patients displayed stable metformin concentrations that never exceeded the safe upper limit of 5.0 mg/L. Hyperlactatemia was absent, and HbA1c levels did not change.&nbsp; The study provided solid basis for the continuing metformin treatment in patients with moderate or severe CKD, supporting the recent guidelines on metformin treatment, providing that the dose is adjusted to the eGFR (Lalau JD et al, <em>&nbsp;Diabetes Care </em>2018;43:547-553).</p> Pinelopi Grigoropoulou ##submission.copyrightStatement## Thu, 21 Mar 2019 11:41:19 +0200 PRESS RELEASE IN ONCOLOGY <p>PRESS RELEASE</p> Dimitrios Syrigos ##submission.copyrightStatement## Thu, 21 Mar 2019 11:41:51 +0200